Review

Published on 16 Mar 2023

Emerging mechanistic insights of selective autophagy in hepatic diseases

in Gastrointestinal and Hepatic Pharmacology

Abdul Alim Al-Bari
Yuko Ito
Paul G. Thomes
Manoj B. Menon
Marina García-Macia
Raouf Fadel
Alfreda Stadlin
Nicholas Peake
MoezAlIslam Ezzat Faris
Nabil Eid

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1149809

6,033 views
11 citations

Editorial

Published on 15 Mar 2023

Editorial: Ulcerative colitis disease therapy: Unveiling the molecular mechanisms of well-defined composition from natural plants

in Gastrointestinal and Hepatic Pharmacology

Yi Tao
Kunming Qin
Huan Li
Lihong Hu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1172160

884 views

Clinical Trial

Published on 14 Mar 2023

The effect of high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients. A randomized placebo controlled trial

in Gastrointestinal and Hepatic Pharmacology

Amal Ahmed Mohamed
Ahmed Abdel Halim
Sahar Mohamed
Seham Mohamed Mahmoud
Eman Mohamed Bahgat Eldemiry
Rasha Sobh Mohamed
Mahmoud Maamoun Shaheen
Gina G. Naguib
Nashwa M. Muharram
Mona G. Khalil

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1149967

2,233 views
2 citations

Original Research

Published on 13 Mar 2023

Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study

in Gastrointestinal and Hepatic Pharmacology

Binbin Lv
Longshan Liu
Xiaoman Liu
Min Huang
Xiao Chen
Kejing Tang
Changxi Wang
Pan Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1126765

3,428 views
2 citations

Systematic Review

Published on 13 Mar 2023

Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials

in Gastrointestinal and Hepatic Pharmacology

Yunpeng Gu
Lei Sun
Wei Zhang
Tingting Kong
Run Zhou
Yining He
Chaohua Deng
Luping Yang
Jianing Kong
Yutong Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1102792

8,495 views
16 citations

Mini Review

Published on 08 Mar 2023

The essential effect of mTORC1-dependent lipophagy in non-alcoholic fatty liver disease

in Gastrointestinal and Hepatic Pharmacology

Xiangyun Tan
Xinyu Huang
Zhuhang Lu
Liang Chen
Junjie Hu
Xianxiang Tian
Zhenpeng Qiu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1124003

2,657 views
4 citations

Review

Published on 03 Mar 2023

Potential of natural flavonols and flavanones in the treatment of ulcerative colitis

in Gastrointestinal and Hepatic Pharmacology

Cailan Li
Ying Tang
Yonghao Ye
Manhua Zuo
Qiang Lu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1120616

2,980 views
5 citations

Review

Published on 02 Mar 2023

Krüppel-like factor 15 in liver diseases: Insights into metabolic reprogramming

in Gastrointestinal and Hepatic Pharmacology

Hao Chen
Lan-Lan Li
Yan Du

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1115226

3,019 views
5 citations

Systematic Review

Published on 28 Feb 2023

Neostigmine for non-mild acute pancreatitis: A systematic review and meta-analysis of randomized controlled trials

in Gastrointestinal and Hepatic Pharmacology

Kun He
Yabing Wang
Jianing Li
Xiaoyin Bai
Zihan Yang
Xianlin Han
Dong Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1131974

1,833 views
2 citations

Original Research

Published on 23 Feb 2023

The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator

in Gastrointestinal and Hepatic Pharmacology

Varsha D. Shiragannavar
Nirmala G. Sannappa Gowda
Lakshana D. Puttahanumantharayappa
Shreyas H. Karunakara
Smitha Bhat
Shashanka K. Prasad
Divya P. Kumar
Prasanna K. Santhekadur

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1135952

4,941 views
17 citations

Editorial

Published on 21 Feb 2023

Editorial: Advances in inflammatory bowel disease: Mucosal defense mechanisms against gut inflammation

in Gastrointestinal and Hepatic Pharmacology

Sinéad C. Corr
Gabriella Aviello

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1147936

1,109 views

Original Research

Published on 20 Feb 2023

Brucea javanica oil alleviates intestinal mucosal injury induced by chemotherapeutic agent 5-fluorouracil in mice

in Gastrointestinal and Hepatic Pharmacology

Xinghan Zheng
Liting Mai
Ying Xu
Minghui Wu
Li Chen
Baoyi Chen
Ziren Su
Jiannan Chen
Hongying Chen
Zhengquan Lai

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1136076

2,325 views
2 citations

Original Research

Published on 17 Feb 2023

UHPLC-MS profiles and antidiarrheal activity of Quercus coccinea münchh. and Quercus robur L. employing in vivo technique

in Gastrointestinal and Hepatic Pharmacology

Mohamed S. Mady
Reham R. Ibrahim
Elsayed K. El-Sayed
Mohamed El-Shazly
Lo-Yun Chen
Kuei-Hung Lai
Fatheya S. El Shaarawy
Fatma A. Moharram

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1120146

1,979 views
3 citations

Original Research

Published on 16 Feb 2023

Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury

in Gastrointestinal and Hepatic Pharmacology

Yu-Ting Xiong
Jian-Fei Wang
Xiao-Xia Niu
Yi-Ming Fu
Ke-Xin Wang
Chun-Yan Wang
Qian-Qian Li
Jian-Jun Wang
Jun Zhao
Dong Ji

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1071709

1,638 views
2 citations

Original Research

Published on 15 Feb 2023

Improvement of obesity-induced fatty liver disease by intermittent hypoxia exposure in a murine model

in Gastrointestinal and Hepatic Pharmacology

Liya Chen
Yao Wang
Weikun Zheng
Hu Zhang
Yan Sun
Yiping Chen
Qi Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1097641

2,359 views
2 citations

Study Protocol

Published on 15 Feb 2023

Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study)

in Gastrointestinal and Hepatic Pharmacology

Huaizhu Guo
Siqi Lu
Jindong Zhang
Chen Chen
Yanlin Du
Kun Wang
Liping Duan

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1121435

41,061 views
5 citations

Navigation group

Articles

Emerging mechanistic insights of selective autophagy in hepatic diseases

Editorial: Ulcerative colitis disease therapy: Unveiling the molecular mechanisms of well-defined composition from natural plants

The effect of high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients. A randomized placebo controlled trial

Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study

Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials

The essential effect of mTORC1-dependent lipophagy in non-alcoholic fatty liver disease

Potential of natural flavonols and flavanones in the treatment of ulcerative colitis

Krüppel-like factor 15 in liver diseases: Insights into metabolic reprogramming

Neostigmine for non-mild acute pancreatitis: A systematic review and meta-analysis of randomized controlled trials

The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator

Editorial: Advances in inflammatory bowel disease: Mucosal defense mechanisms against gut inflammation

Brucea javanica oil alleviates intestinal mucosal injury induced by chemotherapeutic agent 5-fluorouracil in mice

UHPLC-MS profiles and antidiarrheal activity of Quercus coccinea münchh. and Quercus robur L. employing in vivo technique

Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury

Improvement of obesity-induced fatty liver disease by intermittent hypoxia exposure in a murine model

Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study)